SAS Output

18-JUN-2018 6:10

LUNG ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1400-SCCA,Adv, Biomarker Master 1 Y 1 Specimen Submission   1682 384 230 123 34 4 07/08/2014 441 217
            1682 384 230 123 34 4      
 
    2 Y 17 S1400G   63 37 23 15 2 0      
        2 S1400A   160 0 0 0 0 0 07/08/2014    
        21 S1400F   60 60 47 22 7 2      
        25 S1400K   30 30 30 20 5 1      
        3 S1400B   53 0 0 0 0 0      
        4 S1400C   88 0 0 0 0 0      
        5 S1400D   92 0 0 0 0 0      
        6 S1400E   16 0 0 0 0 0      
        7 S1400I   700 143 45 15 0 0      
            1262 270 145 72 14 3      
 
    3 P 10 S1400I   13 7 5 1 0 0      
        18 S1400G   10 5 2 0 0 0      
        22 S1400F   15 15 12 5 2 0      
        8 S1400B   1 0 0 0 0 0 07/08/2014    
            39 27 19 6 2 0      
 
    4 P 23 S1400F   3 3 3 1 1 0 07/08/2014    
            3 3 3 1 1 0      
 
  S1400A-Non-Match: MEDI4736 1 N 1 MEDI4736 140 78 0 0 0 0 0 07/31/2014    
        2 Docetaxel   38 0 0 0 0 0      
            116 0 0 0 0 0      
 
    2 Y 3 MEDI4736 140 4 1 0 0 0 0 07/31/2014    
            4 1 0 0 0 0      
 
  S1400F-Non-Match: MEDI4736 + Tremelimumab 1 Y 1 MEDI4736 + Tremelimumab 132 21 21 17 8 4 1 11/30/2017   220
            21 21 17 8 4 1      
 
  S1400G-HRRD: Talazoparib (BMN 673) 1 Y 1 Talazoparib (BMN 673) 60 48 31 15 8 1 0 03/03/2017 438 217
            48 31 15 8 1 0      
 
  S1400K-c-Met: ABBV-399 (Process II) 1 Y 1 ABBV-399 (Process II) 44 15 15 15 14 2 0 03/16/2018   204
            15 15 15 14 2 0      
 
  8811-NSCLC, Stage III,ChemoRT+ABT-888 1 N 5 RT+Pac+Carbo+blinded drug 132 18 6 0 0 0 0 01/24/2013 35 18
        6 RT+Pac+Carbo+blinded drug   14 2 0 0 0 0      
            32 8 0 0 0 0      
 
    2 Y 8 Pac + Carbo + blinded drug 132 23 16 1 0 0 0 01/24/2013    
            23 16 1 0 0 0      
 
Yes A081105-ALCHEMIST1, EGFR mut, Erlotinib 1 E Total Registrations   39 17 8 3 0 0 04/01/2015   254
            39 17 8 3 0 0      
 
  A151216-ALCHEMIST0 - screening 1 E Total Registrations   525 228 113 57 22 3 12/16/2014 466 257
            525 228 113 57 22 3      
 
  C30610-SCLC, Thoracic RT 1 E Total Registrations   56 6 1 1 0 0 05/14/2008 211 114
            56 6 1 1 0 0      
 
  E4512-ALCHEMIST2, ALK mut, Crizotinib 1 E Total Registrations   8 5 1 1 0 0 02/29/2016 474 255
            8 5 1 1 0 0      
 
  NRGCC003-SCLC, PCI or HA-PCI 1 E Total Registrations   4 3 0 0 0 0 10/20/2016 318 138
            4 3 0 0 0 0      
 
    2 E Total Registrations   4 3 0 0 0 0 10/20/2016    
            4 3 0 0 0 0      
 
No A151216-ALCHEMIST0 - screening 0 E Total Registrations   531 227 112 56 22 3 12/16/2014 466 257
            531 227 112 56 22 3      
 
  EA5142-ALCHEMIST3, Non-match, Nivolumab 1 E Total Registrations   49 35 19 8 3 1 08/03/2016 420 237
            49 35 19 8 3 1      
 

18-JUN-2018 6:10

LUNG Open Studies with No Registrations

The REPORT Procedure

Detailed and/or summarized report

Table 1

Study Registration/Phase Open Date
S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC 1 Neoadjuvant Therapy 03-Nov-17
  2 Surgery 03-Nov-17
  3 Maintenance 03-Nov-17